Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 11:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 210 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NET Clear all
Completed Not applicable Interventional

Diet Education Program for Stage I-IV Colorectal Cancer Survivors

NCT04597151
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional Results available

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

NCT00610129
View directory record Official record
Conditions
Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors
Interventions
MK-0646
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional Results available

A Helping Hand Among Low-Income Patients

NCT02147522
View directory record Official record
Conditions
Depression, Diabetes, Heart Disease
Interventions
Self-care management
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
El Monte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 25, 2026, 11:05 PM EDT
Active, not recruiting Not applicable Interventional

Wishes to Improve Support and Humanity at End-of-life in Safety-net Hospitals

NCT06277310
View directory record Official record
Conditions
End of Life
Interventions
3 Wishes Project
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Los Angeles, California • Sylmar, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Withdrawn Phase 2 Interventional

Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation

NCT00793013
View directory record Official record
Conditions
Acute Lung Injury, Adult Respiratory Distress Syndrome, Kidney Injury
Interventions
Volume-Cycled Assist-Control (AC) mode, Airway Pressure Release Ventilation (APRV) mode
Device
Lead sponsor
University of Tennessee, Chattanooga
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System

NCT02613260
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
FIT Outreach
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years to 75 Years
Enrollment
13,470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2019 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting Phase 2 Interventional

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

NCT04924075
View directory record Official record
Conditions
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor, HIF-2α Mutated Cancers
Interventions
Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • Warrenville, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue

NCT04144257
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
[F-18]PBR06, [C-11]Methylreboxetine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Inpatient Capture: A Mixed Methods Study to Develop an Inpatient Lung Cancer Screening Program in a Safety Net Hospital.

NCT06876831
View directory record Official record
Conditions
Lung Cancer Screening Program
Interventions
Shared decision making for LDCT (3 potential outcomes LDCT on discharge, scheduled date of LDCT, or Lung Cancer Screening referral), Inpatient Tobacco Cessation Counseling (Handouts, NYC Quits number, Medication Recommendations to primary team, Smoking cessation referral)
Other · Behavioral
Lead sponsor
Physician Affiliate Group of New York
Other
Eligibility
50 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

NCT05050942
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
CAM2029, Octreotide LAR, Lanreotide ATG
Drug
Lead sponsor
Camurus AB
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
15
States / cities
Phoenix, Arizona • Santa Monica, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting No phase listed Observational

A Prospective, Multicenter, Single-arm MAC-PD Cohort: a NTM-NET and ESGMYC Collaborative Study

NCT05906316
View directory record Official record
Conditions
Mycobacterium Avium Complex Pulmonary Disease
Interventions
Not listed
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 4 Interventional

Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA

NCT00732524
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glipizide, Glipizide and Glargine
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2008 · Synced Oct 25, 2026, 11:05 PM EDT
Withdrawn Phase 2 Interventional

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

NCT06233903
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma, Paraganglioma
Interventions
18F-mFBG
Drug
Lead sponsor
Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional

Inpatient Smokers and LDCT Screening RCT

NCT03276806
View directory record Official record
Conditions
Lung Cancer, Shared Decision Making
Interventions
tobacco dependence/smoking cessation counseling, SDM, Decision Aid, LDCT brochure
Behavioral · Other
Lead sponsor
Boston University
Other
Eligibility
55 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PREVENT Pilot HPV - Related Cancers Trial

NCT06738355
View directory record Official record
Conditions
HPV Vaccination, Uptake Vaccination, Series Completion
Interventions
PREVENT
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 2 Interventional

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

NCT02279602
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
fosbretabulin
Drug
Lead sponsor
Mateon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Stanford, California • Lexington, Kentucky • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acid-Base Compensation in Chronic Kidney Disease

NCT02427594
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Controlled diet
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting Phase 1 Interventional

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

NCT06441331
View directory record Official record
Conditions
Somatostatin Receptor Positive, NETs, Lymphoma, Solid Tumor, CNS Tumors, Rhabdomyosarcoma, Peripheral Primitive Neuroectodermal Tumor, GIST
Interventions
Lutetium Lu 177-Edotreotide, Amino Acid Solution
Drug · Other
Lead sponsor
ITM Solucin GmbH
Industry
Eligibility
24 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
4
States / cities
San Francisco, California • Cincinnati, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
View directory record Official record
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
Lutathera, 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot), 2.5% Lys-Arg sterile amino acid solution, High dose 60 mg octreotide long-acting repeatable
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting Phase 1 Interventional

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

NCT07473713
View directory record Official record
Conditions
Osteopenia
Interventions
veverimer daily, veverimer every other day, Placebo
Drug · Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 4 Interventional Results available

Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care

NCT03093415
View directory record Official record
Conditions
Hepatitis C, Substance Use Disorders, Substance Abuse, Intravenous
Interventions
elbasvir-grazoprevir (50 mg/100 mg)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 25, 2026, 11:05 PM EDT
Withdrawn Phase 2 Interventional

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

NCT04276597
View directory record Official record
Conditions
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions
177Lu-DOTATOC
Drug
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 25, 2026, 11:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

NCT02936323
View directory record Official record
Conditions
Neuroendocrine Tumors, Carcinoma, Small Cell Lung, Neuroendocrine Carcinoma
Interventions
PEN-221
Drug
Lead sponsor
Tarveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 25, 2026, 11:05 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics of Appendix Cancer Study

NCT05734430
View directory record Official record
Conditions
Appendix Cancer, Appendiceal Cancer, Appendiceal Neoplasms, Appendiceal Mucinous Neoplasm, Appendiceal Adenocarcinoma, Appendiceal Carcinoid Tumor, Appendiceal Neoplasm Malignant Secondary, Appendix Adenocarcinoma, Appendix Mucinous Neoplasm, Appendix Tumor, Appendix Cancer Metastatic, Appendix NET, Low-Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Neoplasm, High Grade Appendix Mucinous Adenocarcinoma
Interventions
Genetic profiling, Retrospective tissue procurement
Genetic · Other
Lead sponsor
Andreana Holowatyj, PhD, MSCI
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2034
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 25, 2026, 11:05 PM EDT